Search results for "Clero"

showing 10 items of 2052 documents

Increased structural white and grey matter network connectivity compensates for functional decline in early multiple sclerosis

2016

Background: The pathology of multiple sclerosis (MS) consists of demyelination and neuronal injury, which occur early in the disease; yet, remission phases indicate repair. Whether and how the central nervous system (CNS) maintains homeostasis to counteract clinical impairment is not known. Objective: We analyse the structural connectivity of white matter (WM) and grey matter (GM) networks to understand the absence of clinical decline as the disease progresses. Methods: A total of 138 relapsing–remitting MS patients (classified into six groups by disease duration) and 32 healthy controls were investigated using 3-Tesla magnetic resonance imaging (MRI). Networks were analysed using graph the…

AdultMale0301 basic medicineMultiple SclerosisModularity (biology)DiseaseGrey matterBiologyNerve Fibers MyelinatedYoung Adult03 medical and health sciences0302 clinical medicineImage Processing Computer-AssistedmedicineHumansGray MatterMultiple sclerosisMiddle Agedmedicine.diseaseNetwork dynamicsWhite MatterPathology of multiple sclerosisWhite (mutation)Diffusion Tensor Imaging030104 developmental biologymedicine.anatomical_structureNeurologyFemaleNeurology (clinical)Nerve NetAdaptationNeuroscience030217 neurology & neurosurgeryDemyelinating DiseasesMultiple Sclerosis Journal
researchProduct

Association of CYP2R1 rs10766197 with MS risk and disease progression

2017

Background MS is a neurodegenerative autoimmune disease resulting from a complex interaction of genetic and environmental factors. Among these, vitamin D and genetic variants associated with vitamin D-metabolism gain great attention. The aim of our study was to assess five SNPs in NADSYN1 and CYP2R1 genes in relation to serum 25-OH-vitamin D3 levels in MS patients and controls. Methods 25-OH-vitamin D3 levels and genotyping of CYP2R1- and NADSYN1-SNPs were investigated both in MS patients and in healthy controls. Results The analysis revealed lower 25-OH-vitamin D3 concentrations in MS patients than in controls and an association of rs10766197 CYP2R1 SNP with MS risk. After stratifying MS p…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyPathologyMultiple SclerosisGenotypeSingle-nucleotide polymorphismPolymorphism Single NucleotideSeverity of Illness IndexpolymorphismDisability Evaluation03 medical and health sciencesCellular and Molecular NeuroscienceSex Factors0302 clinical medicineInternal medicinegendermedicineVitamin D and neurologyHumansSNPGenetic Predisposition to DiseaseNADSYN1AlleleCytochrome P450 Family 2GenotypingRetrospective Studiesbusiness.industryMultiple sclerosisCase-control studyvitamin dMiddle Agedmedicine.diseaseMinor allele frequency030104 developmental biologyCase-Control Studiesmultiple sclerosiDisease ProgressionCYP2R1Cholestanetriol 26-MonooxygenaseFemaleCarbon-Nitrogen Ligases with Glutamine as Amide-N-Donorgeneticbusiness030217 neurology & neurosurgeryJournal of Neuroscience Research
researchProduct

Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, “undifferentiated small round cell tumors”. A…

2017

Abstract Background Despite extensive immunohistochemical (IHC) and molecular studies combined with morphologic findings, a group of round/ovoid cell tumors histologically similar to Ewing sarcomas (ES) but lacking EWSR1-rearrangements may remain unclassifiable. Design We retrospectively analyzed 41 Ewing-like tumors (formalin-fixed, paraffin-embedded) previously determined as negative or non-informative for EWSR1-rearrangements by FISH and/or RT-PCR. A new histopathology revision and additional IHC and molecular analyses were carried out in order to investigate whether additional IHC and/or molecular testing in combination with the morphological findings may help in reaching a definitive d…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyAdolescentDesmoplastic small-round-cell tumorSarcoma EwingSclerosing rhabdomyosarcomaImmunophenotypingPathology and Forensic MedicineYoung Adult03 medical and health sciences0302 clinical medicineBiomarkers TumormedicineHumansStromal tumorChildAgedRetrospective StudiesHomeodomain ProteinsGiSTbusiness.industryNuclear ProteinsCell DifferentiationGeneral MedicineMiddle AgedPrognosismedicine.diseaseImmunohistochemistrySynovial sarcomaMolecular TypingHomeobox Protein Nkx-2.2030104 developmental biology030220 oncology & carcinogenesisSarcoma Small CellFemaleSarcomaClear-cell sarcomaRNA-Binding Protein EWSbusinessTranscription FactorsMyoepithelial TumorAnnals of Diagnostic Pathology
researchProduct

The Primitive Palmomental Reflex in Amyotrophic Lateral Sclerosis

2017

<b><i>Background and Purpose:</i></b> The palmomental reflex (PMR) is a primitive reflex that might be released due to inhibition in adulthood. It has been associated with several neurodegenerative conditions. The aim of the present study was to evaluate the frequency of PMR in amyotrophic lateral sclerosis (ALS). <b><i>Patients and Methods:</i></b> Non-demented ALS patients (<i>n</i> = 179) were recruited. Two groups of disease controls were enrolled: (a) non-demented patients with other neurological disorders (NC;<i> n</i> = 86, mean age 60 ± 14 years); (b) healthy subjects, healthy controls (HC; <i>n</i> …

AdultMale0301 basic medicinePrimitive reflexesmedicine.medical_specialtyGastroenterologyPalmomental reflex03 medical and health sciences0302 clinical medicineInternal medicinePrimitive reflexemedicineHumansPalmomental reflexAmyotrophic lateral sclerosisStrokeAmyotrophic lateral sclerosiAgedPyramidal tractsReflex Abnormalbusiness.industryAmyotrophic Lateral SclerosisMiddle Agedmedicine.disease030104 developmental biologymedicine.anatomical_structureIncreased riskNeurologyReflexFemalePyramidal tractNeurology (clinical)business030217 neurology & neurosurgeryThenar eminenceEuropean Neurology
researchProduct

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

2017

Background: The effect of dimethyl fumarate (DMF) on circulating lymphocyte subsets and their contribution as predictors of clinical efficacy have not yet been investigated in multiple sclerosis (MS). Objective: To evaluate lymphocytes and lymphocyte subsets (analyzed 6 months after DMF start) in MS patients with and without disease activity after 1 year of treatment in a retrospective study. Methods: Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Untreated MS patients ( n = 40) were compared to those 6 months after onset of DMF treatment ( n = 51). Clinical and magnetic resonance imaging (MRI) disease activity of DMF-treated patients were assessed in the first year un…

AdultMale0301 basic medicineTreatment responseMultiple SclerosisAdolescentDimethyl FumarateAntigens CD19CD4-CD8 RatioCD8-Positive T-LymphocytesPharmacologyStatistics NonparametricReduction (complexity)Young Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningLymphopeniamedicineHumansCytotoxic T cellLongitudinal StudiesLymphocyte CountClinical efficacyRetrospective StudiesB-LymphocytesDimethyl fumarateChemistrybusiness.industryMultiple sclerosisMiddle AgedFlow Cytometrymedicine.diseaseMagnetic Resonance ImagingCross-Sectional StudiesTreatment Outcome030104 developmental biologyROC CurveNeurologyDisease ProgressionFemaleNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgeryFollow-Up StudiesLymphocyte subsetsMultiple Sclerosis Journal
researchProduct

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

2015

Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS). Methods: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were e…

AdultMale0301 basic medicineamyotrophic lateral sclerosismedicine.medical_specialtyALS - TUDCA - clinical trialmedicine.drug_classPilot ProjectsAmyotrophic lateral sclerosis; Cholic acids; Tauroursodeoxycholic acid; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Drug Therapy Combination; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Riluzole; Taurochenodeoxycholic Acid; Outcome Assessment (Health Care); Neurology; Neurology (clinical)PlaceboNeuroprotectionGastroenterologyTaurochenodeoxycholic AcidOutcome Assessment (Health Care)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodDrug TherapyInternal medicinemedicineCholic acidHumansAmyotrophic lateral sclerosisAdverse effectAmyotrophic lateral sclerosiAgedtauroursodeoxycholic acidRiluzoleBile acidbusiness.industryTauroursodeoxycholic acidMiddle Agedmedicine.diseaseRiluzoleSurgerySettore MED/26 - NEUROLOGIANeuroprotective Agentscholic acids030104 developmental biologyNeurologychemistryTolerabilityCombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugEuropean Journal of Neurology
researchProduct

Application of tRNS to improve multiple sclerosis fatigue: a pilot, single-blind, sham-controlled study

2019

We evaluated the effects of transcranial random noise stimulation (tRNS) on fatigue in 17 subjects with relapsing–remitting multiple sclerosis with low physical disability. Two different patient groups underwent real or sham stimulation for 10 days, targeting the primary motor cortex of the dominant side or contralateral to the most compromised limb. In the ‘real group’, beneficial effects were observed using the Modified Fatigue Impact Scale (p = 0.04; physical subscale: p = 0.03), the subscales ‘change in health’ (p = 0.006) and ‘role limitations due to physical problems’ (p = 0.001) of the Multiple Sclerosis Quality of Life-54, and by assessing the patient impression of perceived fatigue…

AdultMale0301 basic medicinemedicine.medical_specialtyPhysical disabilityNeurologyFatigue treatmentStimulationTranscranial Direct Current StimulationSeverity of Illness IndexPlacebosYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicinePhysical medicine and rehabilitationOutcome Assessment Health CaremedicineHumansMultiple sclerosiSingle-Blind MethodBeneficial effectsFatigueBiological Psychiatrybusiness.industryMSQoL-54Multiple sclerosisMotor CortextRNSmedicine.diseaseFatigue impact scalePsychiatry and Mental health030104 developmental biologyPrimary motor areaNeurologyQuality of LifeFemaleMFISNeurology (clinical)Single blindPrimary motor cortexbusiness030217 neurology & neurosurgeryJournal of Neural Transmission
researchProduct

Lomitapide affects HDL composition and function

2016

Abstract Background Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH). Methods and results Four HoFH patients were treated with increasing dosages of lomitapide. Lomitapide decreased LDL-C (range −34 to −89%). Total HDL-C levels decreased (range −16 to −34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range −39 to −99%). The changes of total, ABCG1- and SR-BI-me…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaHDLHomozygous familial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type IIYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineIn patientClinical efficacyHyperlipoproteinemia Type IICholesterolbusiness.industryCholesterol HDLHomozygotenutritional and metabolic diseasesCholesterol LDLCholesterol efflux capacityAtherosclerosismedicine.diseaseCholesterol lowering drugsLomitapideLomitapideCholesterolPhenotypeTreatment Outcome030104 developmental biologyEndocrinologychemistryBenzimidazolesFemalelipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol lowering drugHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins HDLCardiology and Cardiovascular MedicinebusinessATP Binding Cassette Transporter 1Atherosclerosis
researchProduct

Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory.

2007

Background and PurposeMeasures to detect important effects related to physical therapy interventions must be able to detect an important change. The purpose of this study was to select the most responsive physical functioning measures for multiple sclerosis (MS) using the International Classification of Functioning, Disability and Health (ICF) as a framework.SubjectsThe participants were 120 people with MS who were ambulatory from a population-based sample.MethodsPhysical functioning was assessed by quantitative clinical measures of activities (n=5) and body functions (n=7) and by self-reported performance in self-care, mobility, and domestic life domains in the activities and participation…

AdultMale030506 rehabilitationmedicine.medical_specialtyActivities of daily livingMultiple SclerosisPopulationPsychological interventionPhysical Therapy Sports Therapy and RehabilitationStatistics Nonparametric03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationInternational Classification of Functioning Disability and HealthSurveys and QuestionnairesActivities of Daily LivingmedicineHumansDisabled Persons10. No inequalityeducationAgededucation.field_of_studyExpanded Disability Status ScaleReceiver operating characteristicMiddle AgedTest (assessment)Self CareROC CurveAmbulatoryPhysical therapyFemale0305 other medical sciencePsychology030217 neurology & neurosurgeryPhysical therapy
researchProduct

Moral Cognition and Multiple Sclerosis: A Neuropsychological Study

2017

Objectives Recent literature proved that social cognition impairments may characterize the neuropsychological profile of Multiple Sclerosis (MS) patients. However, little is still known about moral cognition in MS. In this study, we evaluated non-social, social, and moral cognitive performances in 45 relapsing-remitting MS patients. Methods Patients underwent the Brief International Cognitive Assessment for Multiple Sclerosis battery, the Cognitive Estimation and Stroop tasks, the Ekman-60 Faces test, the Reading the Mind in the Eye and Story-based Empathy task. Additionally, a task of moral dilemmas including both "instrumental" and "incidental" conditions was administered to patients. For…

AdultMale050103 clinical psychologymedia_common.quotation_subjectMoral cognitionEmotionsTheory of MindMoral judgmentEmpathyNeuropsychological TestsMoralsMultiple sclerosisJudgmentYoung AdultCognitionMultiple Sclerosis Relapsing-RemittingSocial cognitionTheory of mindmedicineHumans0501 psychology and cognitive scienceshealth care economics and organizationsmedia_commonEmotions/emotional processing05 social sciencesNeuropsychologyCognitionGeneral MedicineEmotional detachmenthumanitiesPsychiatry and Mental healthClinical PsychologyNeuropsychology and Physiological PsychologyCase-Control StudiesFemaleSettore MED/26 - Neurologiamedicine.symptomEmpathyPsychologyAttributionStroop effectClinical psychology
researchProduct